Luteolin attenuates vascular smooth muscle cell senescence by regulating ferroptosis through SLC7A11/GPX4 signaling pathway
CSTR:
Author:
Affiliation:

(1.Chinese PLA Medical School, Beijing 100853, China;2.Institute of Geriatrics, Second Medical Center, Chinese PLA General Hospital, Beijing 100853, China;3. Faculty of Clinical Medicine, School of Medicine, Nankai University, Tianjin 300071, China)

Clc Number:

Fund Project:

This work was supported by the National Key Research and Development Program of China(2022YFC360240O).

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    Objective To investigate the molecular mechanism by which luteolin (Lut) alleviates vascular smooth muscle cells (VSMCs) senescence by regulating ferroptosis via the solute carrier family 7 member 11 (SLC7A11)/glutathione peroxidase 4 (GPX4) signaling pathway, thereby providing novel insights for the prevention and treatment of vascular aging-related diseases. MethodsMouse vascular smooth muscle cells (MOVAS) were subjected and randomly divided into blank control group (Con group), Lut group (5 μmol/L Lut for 24 h), doxorubicin group (DOX group, 1 μmol/L DOX for 24 h), and combined treatment group (DOX+Lut group, pretreatment of 5 μmol/L Lut for 24 h followed by DOX treatment). Cell senescence and viability were evaluated using senescence-associated β-galactosidase (SA-β-gal) staining and cell counting kit-8 (CCK-8) assay, respectively. The expression of senescence-related proteins (P53, P21, P16) and ferroptosis pathway proteins (SLC7A11, GPX4) was detected by Western blot. Reactive oxygen species (ROS) production was measured by flow cytometry. Lipid peroxidation and intracellular ferrous iron (Fe2+) levels were detected using lipid peroxidation fluorescent probes and FerroOrange fluorescent probe, respectively. Additionally, glutathione (GSH) and malondialdehyde (MDA) contents in cell lysates were measured. SLC7A11 inhibitor Erastin was used to intervene ferroptosis to observe the changes in senescence phenotypes. GraphPad Prism 10.0 software was employed for data analysis. Multiple-group comparison was performed using one-way ANOVA followed by Tukey′s post hoc test, and intergroup comparison was applied using a two-tailed independent sample t test. Results Compared with the Con group, the DOX group exhibited significantly decreased cell viability (IC50=1.799 μmol/L) and an obviously increased proportion of SA-β-gal-positive senescent cells (approximately 63%, P<0.05), accompanied with upregulated senescence proteins (P53, P21, P16), elevated ROS and lipid peroxidation levels, marked accumulation of Fe2+, reduced GSH content, and notably downregulated expression of SLC7A11 and GPX4 proteins (P<0.05). The addition of Lut pretreatment remarkably improved the aforementioned indicators, such as the IC50 value increasing to 2.192 μmol/L, the proportion of senescent cells decreasing to approximately 38%, and restored protein levels of SLC7A11 and GPX4 when compared with the levels in the DOX group (P<0.05). Conclusion Lut effectively inhibits DOX-induced ferroptosis and alleviates VSMC senescence by activating the SLC7A11/GPX4 signaling pathway, providing a theoretical basis for the treatment of vascular aging-related diseases.

    Reference
    Related
    Cited by
Get Citation
Related Videos

Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:August 29,2025
  • Revised:
  • Adopted:
  • Online: March 09,2026
  • Published:
Article QR Code